Humedix signs HA Filler supply contract…“Expansion to the Middle East”
[by Yu, Suin] 카지노 룰렛 사이트 Group participated in a dermatology exhibition in Dubai, Middle East, unveiling the group’s innovative products and cutting-edge technologies to enhance global competitiveness.
On April 17, Humedix, 카지노 룰렛 사이트 Meditech, and 카지노 룰렛 사이트 BioPharma announced that the group companies had participated in this year’s Dubai World Dermatology and Laser Conference & Exhibition, (Dubai Derma 2025), held this week from April 14 to 16 at the Dubai World Trade Center, Dubai, United Arab Emirates.
카지노 룰렛 사이트 Derma 2025 is the 24th edition of the largest dermatology professional gathering in the Middle East and North Africa (MENA). The event featured participation from leading companies and experts in the field of medical devices, aesthetics, and cosmeceuticals (a combination of cosmetics and pharmaceuticals) and included conferences to promote the development of the skin care industry in the Middle East.
At the exhibition, Humedix signed a supply contract for its famous hyaluronic acid (HA) filler, Elravie, covering Saudi Arabia, Lebanon, and Syria, establishing a bridgehead for expanding into the Middle Eastern market.
Elravie Premier is a filler that uses Humedix’s proprietary technology to maintain the viscosity of HA. Elravie has received product approval in Korea, the European Union (CE), China (NMPA), and Russia (RZN). Elravie is currently being exported to 19 countries, including China and Brazil.
CEO of Humedix, Kang Min-jong, said, “Elravie has already earned strong trust from Middle Eastern buyers thanks to its proven efficacy and safety. We plan to actively expand into the Middle Eastern market by advancing into Saudi Arabia, one of the region’s key markets.”
카지노 룰렛 사이트 Meditech received attention for ‘Dermashine Pro’ from buyers at the exhibition. ‘Dermashine Pro’ is an automatic mesotherapy injector equipped with an automatic pressure detection system, which injects high-molecular-weight hyaluronic acid into the entire face. 카지노 룰렛 사이트 Meditech achieved cumulative sales of 20,000 units of the ‘Dermashine’ product series as of the end of 2024.
CEO of 카지노 룰렛 사이트 Meditech, Lee Jin-suk, said, “Dubai Derma 2025 opened up many new business opportunities for 카지노 룰렛 사이트 Meditech, and we plan to expand into the global market. We will further strengthen our position in the global medical device market by enhancing overseas marketing.”
카지노 룰렛 사이트 BioPharma attracted significant attention from visitors for its botulinum toxin products and proprietary technology at the exhibition. 카지노 룰렛 사이트 BioPharma has obtained product approval in 15 countries, including Russia, Southeast Asia (Thailand, etc.), and the Middle East (Iraq, etc.) for its botulinum toxin and is currently in the process of obtaining product approval in China as well.
According to a company official, “Leveraging our participation in 카지노 룰렛 사이트 Derma 2025, we will continue to highlight the competitive advantages of our product and secure strategic partnerships to expand our presence in the Middle East.”